The Pharma Data
MAY 15, 2021
Product Name: The Longevity Breakthrough Your Doctor Won't Tell You About. Click here to get The Longevity Breakthrough Your Doctor Won't Tell You About at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.
Drug Discovery World
AUGUST 16, 2023
Triple negative cancers are not driven by any of the three molecules that can be blocked by targeted hormone receptor drugs – the HER2 protein and two hormone receptors for oestrogen and progesterone – and so current treatment options are limited.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 31, 2022
Amir Abdo Alsharabasy, a CÚRAM doctoral candidate working in the laboratory of Professor Abhay Pandit, is working on the design of nitric oxide scavengers to form a new treatment approach for this aggressive form of breast cancer.
The Pharma Data
FEBRUARY 1, 2021
1, 2021 (American Heart Association News) — Medical science has come a long way since the days of “bikini medicine,” when the only time doctors managed a woman’s health differently than a man’s was when treating the parts of her body found under a bikini. MONDAY, Feb. It’s not that simple.”
The Pharma Data
MAY 14, 2021
Metabolic Breakthrough Rebalances Your “Hot Zone Hormones” So Any Woman Over 35 Can Blast Off Belly Fat, Shape Flabby Muscle And See Your Most Attractive,Youthful, And Energized Body Ever In Only 30 Days WITHOUT Suffering Through Restrictive Diets Or Trying To Starve Yourself Skinny. Helping you Permanently Blast off Belly Fat.
The Pharma Data
JANUARY 21, 2021
Doctors need better tools to evaluate the status of COVID-19 patients as early as possible because many of the treatments—such as monoclonal antibodies—are in short supply, and we know that some patients will get better without intensive treatments,” said co-senior author Andrew E. The research was published in the journal JCI Insight.
The Pharma Data
JANUARY 4, 2021
TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Dual blockade of the TIGIT and PD-L1 pathways. receptors. .
Expert insights. Personalized for you.
52 
Let's personalize your content